Blar i NTNU Open på forfatter "Rustad, Even Holth"
-
Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
Rustad, Even Holth; Hultcrantz, Malin; Yellapantula, Venkata D; Akhlaghi, Theresia; Ho, Caleb; Arcila, Maria E; Roshal, Mikhail; Patel, Akshar; Chen, Denise; Devlin, Sean M; Jacobsen, Austin; Huang, Ying; Miller, Jeffrey E; Papaemmanuil, Elli; Landgren, Ola (Peer reviewed; Journal article, 2019)Tracking of clonal immunoglobulin V(D)J rearrangement sequences by next generation sequencing is highly sensitive for minimal residual disease in multiple myeloma. However, previous studies have found variable rates of ... -
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article; Peer reviewed, 2015)In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ... -
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth; Sanders, Mathijs A.; Rye, Morten Beck; Sponaas, Anne-Marit; van der Holt, Bronno; Zweegman, Sonja; Hovig, Eivind; Meza, Leonardo Zepeda; Sundan, Anders; Myklebost, Ola; Sonneveld, Pieter; Waage, Anders (Peer reviewed; Journal article, 2022)We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal composition ... -
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Yang, Rui; Elsaadi, Samah; Misund, Kristine; Abdollahi, Pegah; Vandsemb, Esten; Moen, Siv Helen; Kusnierczyk, Anna; Slupphaug, Geir; Standal, Therese; Waage, Anders; Slørdahl, Tobias Schmidt; Rø, Torstein Baade; Rustad, Even Holth; Sundan, Anders; Hay, Carl; Cooper, Zachary; Schuller, Alwin G.; Woessner, Richard; Borodowski, Alexandra; Menu, Eline; Børset, Magne; Sponaas, Anne-Marit (Peer reviewed; Journal article, 2020)Background PD1/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and ... -
Genetic biomarkers in multiple myeloma
Rustad, Even Holth (Doctoral theses at NTNU;2019: 223, Doctoral thesis, 2019)Multiple myeloma is a cancer of plasma cells in the bone marrow that accounts for 2 % of cancer cases globally. Improved understanding of the molecular basis of this disease has resulted in new treatment options and prolonged ... -
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril; Standal, Therese; Børset, Magne; Beisvag, Vidar; Myklebost, Ola; Meza, Leonardo Zepeda; Hong, Yan Dai; Sundan, Anders; Waage, Anders (Journal article; Peer reviewed, 2017)Circulating tumor DNA is a promising biomarker to monitor tumor load and genome alterations. We explored the presence of circulating tumor DNA in multiple myeloma patients and its relation to disease activity during long-term ... -
PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy
Sponaas, Anne-Marit; Nejati Moharrami, Neda; Feyzi, Emadoldin; Standal, Therese; Rustad, Even Holth; Waage, Anders; Sundan, Anders (Peer reviewed; Journal article, 2015)In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore ... -
Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants
Meyer, Saskia; Blaas, Isaac; Bollineni, Ravi Chand; Delic-Sarac, Marina; Tran, Trung; Knetter, Cathrine; Dai, Kezheng; Madssen, Torfinn Støve; Vaage, John T.; Gustavsen, Alice; Yang, Weiwen; Nissen-Meyer, Lise Sofie Haug; Douvlataniotis, Karolos; Laos, Maarja; Nielsen, Morten Milek; Thiede, Bernd; Søraas, Arne Vasli Lund; Lund-Johansen, Fridtjof; Rustad, Even Holth; Olweus, Johanna (Peer reviewed; Journal article, 2023)The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that mediate escape from neutralizing antibodies. There is also evidence that mutations can cause loss of T cell epitopes. However, studies on ... -
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung; Delic-Sarac, Marina; Hestdalen, Malu Lian; Brodin, Ellen Elisabeth; Rustad, Even Holth; Dai, Ke-Zheng; Vaage, John T.; Nissen-Meyer, Lise Sofie Haug; Sund, Fredrik; Wader, Karin Fahl; Bjørnevik, Anne Turid; Meyer, Peter Albert; Nygaard, Gro Owren; König, Marton; Smeland, Sigbjørn; Lund-Johansen, Fridtjof; Olweus, Johanna; Kolstad, Arne (Peer reviewed; Journal article, 2022)B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 ...